journal
MENU ▼
Read by QxMD icon Read
search

Clinical Therapeutics

journal
https://www.readbyqxmd.com/read/28528719/diabetic-peripheral-neuropathy-and-associated-pain-emerging-and-updated-research
#1
EDITORIAL
John G Ryan
No abstract text is available yet for this article.
May 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28527959/systemic-treatment-patterns-with-advanced-or-recurrent-non-small-cell-lung-cancer-in-japan-a-retrospective-hospital-administrative-database-study
#2
Feng Wang, Sari Mishina, Shinji Takai, T Kim Le, Kenya Ochi, Kotaro Funato, Shozo Matsuoka, Yuichiro Ohe
PURPOSE: Data on the treatment of non-small cell lung cancer (NSCLC) in real-world clinical practice in Japan are limited. This large-scale, retrospective cohort study examined data on patients' characteristics and systemic therapies for advanced or recurrent NSCLC in routine practice in Japan. METHODS: This study used an electronic health records-based database of health claims and Diagnosis Procedure Combination data from 215 consenting hospitals in Japan. Records from April 2008 to September 2015 were analyzed...
May 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28526416/treatment-strategy-for-type-2-diabetes-with-obesity-focus-on-glucagon-like-peptide-1-receptor-agonists
#3
REVIEW
Qiuhe Ji
PURPOSE: The progressive nature of type 2 diabetes mellitus (T2DM) calls for step-wise intensification of therapy for maintaining normal glycemic levels and lowering cardiovascular (CV) risk. Because obesity is a prominent risk factor and comorbidity of T2DM, it further elevates the CV risk in T2DM. Therefore, it is vital to manage weight, obesity, and glycemic parameters for effective T2DM management. Few oral antidiabetic drugs (sulfonylureas and thiazolidinediones) and insulin are not suitable for obese patients with T2DM because these drugs cause weight gain...
May 16, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28522209/corrigendum-to-demographic-and-clinical-characteristics-of-type-2-diabetes-mellitus-patients-initiating-dipeptidyl-peptidase-4-inhibitors-a-retrospective-study-of-uk-general-practice
#4
Abigail Tebboth, Sally Lee, Anna Scowcroft, Paula Bingham-Gardiner, William Spencer, John Bolodeoku, Syed Wasi Hassan
No abstract text is available yet for this article.
May 15, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28495029/the-pharmacokinetics-of-the-cyp3a-substrate-midazolam-after-steady-state-dosing-of-delafloxacin
#5
Susan K Paulson, Rebecca N Wood-Horrall, Randall Hoover, Megan Quintas, Laura E Lawrence, Sue K Cammarata
PURPOSE: Delafloxacin is a novel anionic fluoroquinolone in Phase III development for the treatment of serious skin infections. The objective of this study was to evaluate the effects of delafloxacin on the pharmacokinetics of midazolam, a cytochrome P450 (CYP) 3A substrate. METHODS: CYP3A activity using midazolam as a probe was assessed before and after multiple doses of delafloxacin to reach steady state. In this nonrandomized, open-label, single-sequence, Phase I study, 22 healthy male and female subjects were administered a single 5-mg oral dose of midazolam on days 1 and 8, with oral delafloxacin 450 mg every 12 hours administered from days 3 to 8...
May 8, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28495028/real-world-clinical-outcomes-among-patients-with-type-2-diabetes-receiving-canagliflozin-at-a-specialty-diabetes-clinic-subgroup-analysis-by-baseline-hba1c-and-age
#6
June Felice Johnson, Rahul Parsa, Robert A Bailey
PURPOSE: Canagliflozin, a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM), has demonstrated effectiveness in patients with T2DM receiving care at a specialty diabetes clinic. We report the outcomes in these patients in subgroups classified by baseline hemoglobin A1c (HbA1c) and age. METHODS: This subgroup analysis was based on a review of data from the electronic health records of adults with T2DM who were prescribed canagliflozin at a specialty diabetes clinic and who returned for ≥1 follow-up office visit...
May 8, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28483293/population-pharmacokinetics-of-valproic-acid-in-patients-with-mania-implication-for-individualized-dosing-regimens
#7
Janthima Methaneethorn
PURPOSE: This study characterized the population pharmacokinetic properties of valproic acid in patients with mania and determined potential factors that affect the pharmacokinetic properties of valproic acid in this population. METHODS: Routine therapeutic drug monitoring of valproic acid concentrations, demographic data, and concomitant medications from 206 hospitalized patients with mania were retrospectively collected from Somdet Chaopraya Institute of Psychiatry and Srithanya Hospital, Thailand...
May 5, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28476406/influence-of-cdx2-and-taqi-gene-variants-on-vitamin-d3-modulated-intracellular-chemokine-positive-t-cell-subsets-in-pulmonary-tuberculosis
#8
Murugesan Harishankar, Paramasivam Selvaraj
PURPOSE: We studied the effect of 1,25(OH)2D3 (vitamin D3) on intracellular chemokine-positive T-cell subsets in whole blood cultures of healthy controls and patients with pulmonary tuberculosis. METHODS: Genotyping was performed by the polymerase chain reaction-restriction fragment length polymorphism method. The regulatory role of the Cdx2 and 3'UTR TaqI gene variants on chemokine-positive T-cell subsets was studied from culture filtrate antigen stimulated with or without vitamin D3 treated whole blood cultures of 60 healthy controls and 50 patients with pulmonary tuberculosis...
May 2, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28476405/international-normalized-ratio-is-significantly-elevated-with-rivaroxaban-and-apixaban-drug-therapies-a-retrospective-study
#9
Fanny Ofek, Samuel Bar Chaim, Nirit Kronenfeld, Tomer Ziv-Baran, Matitiahu Berkovitch
PURPOSE: Direct factor Xa inhibitors such as rivaroxaban or apixaban may prolong prothrombin time (PT) and elevate international normalized ratio (INR). However, these tests are not reliable for assessing the anticoagulation effects of these agents. PT assay sensitivity is relatively weak at therapeutic drug concentrations and is subjected to significant variations depending on the reagent used. Conversion of PT to INR may even increase the variability. We conducted a retrospective cross-sectional study aiming to assess the prevalence and extent of INR elevation in hospitalized patients receiving rivaroxaban or apixaban as part of their home medications and to find out whether other existing factors could elevate INR apart from the drug entity itself...
May 2, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28476404/dropout-prevalence-and-associated-factors-in-randomized-clinical-trials-of-adolescents-treated-for-depression-systematic-review-and-meta-analysis
#10
Adriane Isabel Rohden, Mariana Canellas Benchaya, Roger Santos Camargo, Taís de Campos Moreira, Helena M T Barros, Maristela Ferigolo
PURPOSE: Depression currently affects 350 million people, and its prevalence among adolescents is 4% to 8%. Adolescents who abandon antidepressant treatment or drop out of clinical trials are less likely to recover or experience a remission of symptoms because they are not being followed up by a medical team. The objective of this study was to analyze the dropout rates of randomized clinical trials of depressed adolescents receiving treatment with antidepressant drugs and the factors associated with nonadherence by summarizing this information in a systematic review and meta-analysis...
May 2, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28457494/vitamin-d-status-and-the-host-resistance-to-infections-what-it-is-currently-not-understood
#11
Pierre Olivier Lang, Richard Aspinall
PURPOSE: Vitamin D is increasingly thought to play a role in regulating immunity. This comprehensive review updates the current understanding regarding ways in which we believe that vitamin D regulates responsiveness of the immune system and how serum status modulates the host defense against pathogens. METHODS: The literature was searched by using PubMed and Scopus with the following key words: vitamin D, immunity, innate and adaptive immunity, infectious disease, and vaccine response...
April 27, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28454657/vitamin-d-and-atopy
#12
EDITORIAL
Theoharis C Theoharides
No abstract text is available yet for this article.
April 25, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28449868/vitamin-d-and-bronchial-asthma-an-overview-of-data-from-the-past-5-years
#13
REVIEW
Sannette C Hall, Devendra K Agrawal
PURPOSE: Vitamin D is a potent immunomodulator capable of dampening inflammatory signals in several cell types involved in the asthmatic response. Its deficiency has been associated with increased inflammation, exacerbations, and overall poor outcomes in patients with asthma. Given the increase in the prevalence of asthma over the past few decades, there has been enormous interest in the use of vitamin D supplementation as a potential therapeutic option. Here, we critically reviewed the most recent findings from in vitro studies, animal models, and clinical trials regarding the role of vitamin D in treating bronchial asthma...
April 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28449867/cost-effectiveness-of-ingenol-mebutate-gel-for-the-treatment-of-actinic-keratosis-in-greece
#14
Kostas Athanasakis, Nadia Boubouchairopoulou, Filippos Tarantilis, Vasiliki Tsiantou, Stathis Kontodimas, John Kyriopoulos
PURPOSE: The present study aimed to perform a cost-effectiveness analysis of ingenol mebutate (IM) versus other topical alternatives for the treatment of actinic keratosis (AK). METHODS: The analysis used a decision tree to calculate the clinical effects and costs of AK first-line treatments, IM (2-3 days), diclofenac 3% (for 8 or 12 weeks), imiquimod 5% (for 4 or 8 weeks), during a 24-month horizon, using discrete intervals of 6 months. A hypothetical cohort of immunocompetent adult patients with clinically confirmed AK on the face and scalp or trunk and extremities was considered...
April 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28438353/the-role-of-vitamin-d-in-the-immune-system-as-a-pro-survival-molecule
#15
REVIEW
Salvatore Chirumbolo, Geir Bjørklund, Andrea Sboarina, Antonio Vella
PURPOSE: Vitamin D is a fascinating and attractive molecule that has gained particular attention in medicine in recent years. Its immunomodulatory and anti-inflammatory potential might resemble the activity of many nature-derived molecules (eg, flavonoids), but its role in biology was selected during a long evolutionary pathway to dampen the damaging effect of cell stress response and of the immune reaction. In this sense, this molecule can be considered an ancient hormone that serves, in its primary role, as a pro-survival agent...
April 21, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28433400/an-in-home-advanced-robotic-system-to-manage-elderly-home-care-patients-medications-a-pilot-safety-and-usability-study
#16
Pekka Rantanen, Timo Parkkari, Saija Leikola, Marja Airaksinen, Alan Lyles
PURPOSE: We examined the safety profile and usability of an integrated advanced robotic device and telecare system to promote medication adherence for elderly home-care patients. METHODS: There were two phases. Phase I aimed to verify under controlled conditions in a single nursing home (n = 17 patients) that no robotic malfunctions would hinder the device's safe use. Phase II involved home-care patients from 3 sites (n = 27) who were on long-term medication. On-time dispensing and missed doses were recorded by the robotic system...
April 19, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28431767/the-new-drug-conditional-approval-process-in-china-challenges-and-opportunities
#17
REVIEW
Xuefang Yao, Jinxi Ding, Yingfang Liu, Penghui Li
PURPOSE: Our aim was to characterize the newly established new drug conditional approval process in China and discuss the challenges and opportunities with respect to new drug research and development and registration. METHODS: We examined the new approval program through literature review, law analysis, and data analysis. Data were derived from published materials, such as journal articles, government publications, press releases, and news articles, along with statistical data from INSIGHT-China Pharma Databases, the China Food and Drug Administration website, the Center for Drug Evaluation website, the US Food and Drug Administration website, and search results published by Google...
April 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28431766/analysis-of-2-week-data-from-two-randomized-controlled-trials-conducted-in-subjects-with-frequent-heartburn-treated-with-esomeprazole-20-mg
#18
Philip O Katz, Anne Le Moigne, Charles Pollack
PURPOSE: These secondary analyses used data from 2 similarly designed studies in subjects experiencing frequent heartburn to evaluate the efficacy of esomeprazole 20 mg once daily for 2 weeks, which reflects the approved over-the-counter dosage and duration. METHODS: Subjects without endoscopically identified erosive esophagitis who were experiencing heartburn for ≥6 months and ≥4 of 7 days prior to baseline (study 1, N = 368; study 2, N = 349) were randomly assigned to receive double-blind treatment with esomeprazole 40 or 20 mg (administered as esomeprazole magnesium trihydrate 44...
April 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28431765/immune-modulation-by-vitamin-d-special-emphasis-on-its-role-in-prevention-and-treatment-of-cancer
#19
REVIEW
Franco Pandolfi, Laura Franza, Claudia Mandolini, Pio Conti
PURPOSE: Vitamin D has been known to be involved in mineral and bone homeostasis for many years. In the past its main use was in treating osteoporosis and rickets. In recent years it was found that vitamin D is an immune-modulating agent and may also have a role in several diseases, including autoimmune diseases. The immune-modulating effects appear to be mediated by vitamin D interaction with the vitamin D receptor (VDR) that has transcriptional effects and is expressed on various cell types, especially those of the immune system...
April 18, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28420486/vitamins-c-and-d
#20
EDITORIAL
Richard I Shader
No abstract text is available yet for this article.
April 15, 2017: Clinical Therapeutics
journal
journal
27126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"